Increased survival time or better quality of life? Trade-off between benefits and adverse events in the systemic treatment of cancer

Valentí, V.; Ramos, J Guerra; Pérez, Carolina Hernández; Capdevila, Laia; Ruíz, Isabel; Tikhomirova, Lidia; Sanchez, M. Lorente; Juez, Ignacio; Llobera, Montserrat; Sopeña, Eva Martin; Rubio, J.; Salazar, Ramón

doi:10.1007/s12094-019-02216-6

Cited by 12 publications

(9 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The most important attribute in decision making, for both patients and clinicians, was survival benefit. This has been reported in several cancer preference studies [15,16]. However, thorough evaluation of multiple attributes, especially with distinction of short-term and longterm impairments, is novel.…”

Section: Discussionmentioning

confidence: 72%

See 1 more Smart Citation

Patients' and clinicians' preferences in adjuvant treatment for high-risk endometrial cancer: Implications for shared decision making

Post

Mens

Haverkort

et al. 2021

Gynecologic Oncology

View full text Add to dashboard Cite

Desired benefit to choose adjuvant chemotherapy was assessed in endometrial cancer. • Desired benefit varied considerably among and between patients and clinicians. • Patients desired higher survival benefit than clinicians to choose chemoradiotherapy. • Survival benefit and long-term symptoms are most important in decision making. • Patient preferences are strongly influenced by treatment history.

show abstract

Section: Discussionmentioning

confidence: 72%

“…However, thorough evaluation of multiple attributes, especially with distinction of short-term and longterm impairments, is novel. Some studies emphasised the importance of quality of life in general, but without detailed attributes [16,17]. We found that the risk of developing long-term symptoms (i.e.…”

Section: Discussionmentioning

confidence: 82%

Patients' and clinicians' preferences in adjuvant treatment for high-risk endometrial cancer: Implications for shared decision making

Post

Mens

Haverkort

et al. 2021

Gynecologic Oncology

View full text Add to dashboard Cite

show abstract

“…In general, the representativeness of patients was good, although a few studies asked patients to provide answers for a hypothetical situation—for example, what they would choose if they had a different type or stage of cancer [ 29 , 40 ]. Some studies did not clearly report how specific outcomes were selected [ 28 , 29 ], or did not describe selection procedures at all [ 41 , 47 , 48 , 50 ]. Additionally, sometimes it was unclear how quality of life or other attributes were defined or were described to patients [ 27 , 39 ].…”

Section: Resultsmentioning

confidence: 99%

Patient Preferences for Treatment Outcomes in Oncology with a Focus on the Older Patient—A Systematic Review

Seghers

Wiersma

Festen

et al. 2022

Cancers

View full text Add to dashboard Cite

For physicians, it is important to know which treatment outcomes are prioritized overall by older patients with cancer, since this will help them to tailor the amount of information and treatment recommendations. Older patients might prioritize other outcomes than younger patients. Our objective is to summarize which outcomes matter most to older patients with cancer. A systematic review was conducted, in which we searched Embase and Medline on 22 December 2020. Studies were eligible if they reported some form of prioritization of outcome categories relative to each other in patients with all types of cancer and if they included at least three outcome categories. Subsequently, for each study, the highest or second-highest outcome category was identified and presented in relation to the number of studies that included that outcome category. An adapted Newcastle–Ottawa Scale was used to assess the risk of bias. In total, 4374 patients were asked for their priorities in 28 studies that were included. Only six of these studies had a population with a median age above 70. Of all the studies, 79% identified quality of life as the highest or second-highest priority, followed by overall survival (67%), progression- and disease-free survival (56%), absence of severe or persistent treatment side effects (54%), and treatment response (50%). Absence of transient short-term side effects was prioritized in 16%. The studies were heterogeneous considering age, cancer type, and treatment settings. Overall, quality of life, overall survival, progression- and disease-free survival, and severe and persistent side effects of treatment are the outcomes that receive the highest priority on a group level when patients with cancer need to make trade-offs in oncologic treatment decisions.

show abstract

“…RWD aids communication between physicians and patients by informing shared decision-making with regard to treatment options and available patient support programs [ 20 ]. In some cases, patients may prefer improved quality of life over an increased survival benefit, or may have concerns over specific toxicities [ [21] , [22] , [23] , [24] ].…”

Section: Mature Breast Cancer Drugsmentioning

confidence: 99%

The emerging role of real-world data in advanced breast cancer therapy: Recommendations for collaborative decision-making

et al. 2022

View full text Add to dashboard Cite

Among stakeholders and decision-makers in advanced breast cancer, the demand for insights from realworld data (RWD) is increasing. Although RWD can be used to support decisions throughout different stages of a breast cancer drug's life cycle, barriers exist to its use and acceptance. We propose a collaborative approach to generating and using RWD that is meaningful to multiple stakeholders, and encourage frameworks toward international guidelines to help standardize RWD methodologies to achieve more efficient use of RWD insights.

show abstract

Increased survival time or better quality of life? Trade-off between benefits and adverse events in the systemic treatment of cancer

Cited by 12 publications

References 17 publications

Patients' and clinicians' preferences in adjuvant treatment for high-risk endometrial cancer: Implications for shared decision making

Patients' and clinicians' preferences in adjuvant treatment for high-risk endometrial cancer: Implications for shared decision making

Patient Preferences for Treatment Outcomes in Oncology with a Focus on the Older Patient—A Systematic Review

The emerging role of real-world data in advanced breast cancer therapy: Recommendations for collaborative decision-making

Contact Info

Product

Resources

About